Upstream Bio (UPB) Revenue & Revenue Breakdown
Upstream Bio Revenue Highlights
Latest Revenue (Y)
$2.85M
Latest Revenue (Q)
$773.00K
Upstream Bio Revenue by Period
Upstream Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $2.85M | 20.42% |
| 2024-12-31 | $2.37M | -0.42% |
| 2023-12-31 | $2.38M | 96.37% |
| 2022-12-31 | $1.21M | - |
Upstream Bio generated $2.85M in revenue during NA 2025, up 20.42% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Upstream Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $773.00K | -25.24% |
| 2026-03-31 | $1.03M | 54.79% |
| 2025-12-31 | $668.00K | -2.20% |
| 2025-09-30 | $683.00K | -27.11% |
| 2025-06-30 | $937.00K | 65.55% |
| 2025-03-31 | $566.00K | -7.67% |
| 2024-12-31 | $613.00K | 0.99% |
| 2024-09-30 | $607.00K | 19.02% |
| 2024-06-30 | $510.00K | -20.31% |
| 2024-03-31 | $640.00K | 42.22% |
| 2023-12-31 | $450.00K | -27.54% |
| 2023-09-30 | $621.00K | - |
Upstream Bio generated $773.00K in revenue during Q2 2026, up -25.24% compared to the previous quarter, and up 136.57% compared to the same period a year ago.
Upstream Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVAX | Novavax | $1.12B | $56.70M |
| SNDX | Syndax Pharmaceuticals | $172.35M | $72.79M |
| WVE | Wave Life Sciences | $42.73M | $2.27M |
| RLAY | Relay Therapeutics | $15.36M | $350.00K |
| ZBIO | Zenas BioPharma | $10.00M | $1.00M |
| UPB | Upstream Bio | $2.85M | $773.00K |
| NTLA | Intellia Therapeutics | - | $7.66M |
| PHVS | Pharvaris | - | - |
| SYRE | Spyre Therapeutics | - | - |
| AMLX | Amylyx Pharmaceuticals | - | - |